Drug Guidance for Subsidy 06/02/2026 Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease NRDonanemab and lecanemab are not recommended for inclusion on the MOH List of Subsidised Drugs for ... See all × 06/02/2026 Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease NRDonanemab and lecanemab are not recommended for inclusion on the MOH List of Subsidised Drugs for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease. NRThis is because the current available evidence shows that the treatment effects for donanemab and for lecanemab were small with uncertain clinical meaningfulness, and the short trial durations limited the understanding of the treatments’ impact over the full course of the disease. NRGiven the uncertainty in clinical benefit and significant additional healthcare resources required to assess treatment eligibility and risks, as well as for regular magnetic resonance imaging (MRI) monitoring, funding these drugs would not represent a cost-effective use of healthcare resources and could place undue strain on the healthcare system.
Post Marketing Information PEM 08/12/2025 LEQEMBI® (lecanemab) INJECTION FOR INTRAVENOUS USE | 100 mg/mL: A Guide for Healthcare Professionals PAC 02/05/2025 LEQEMBI® (lecanemab) INJECTION FOR INTRAVENOUS USE | 100 mg/mL: Wallet Card
INTRAVENOUS Select a brand starting with the letter: L LEQEMBI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML [SIN17228P]